| Trial ID: | L1338 |
| Source ID: | NCT01595841
|
| Associated Drug: |
Sirolimus
|
| Title: |
Sirolimus Use in Angioplasty for Vascular Access Extension
|
| Acronym: |
SAVE
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End Stage Renal Disease|Venous Stenosis
|
| Interventions: |
DRUG: Sirolimus
|
| Outcome Measures: |
Primary: Comparison of the sirolimus group to the control group from time of assisted primary and secondary patency rates to access abandonment, Comparison of the sirolimus group to the control group from time of assisted primary and secondary patency rates to access abandonment, 12 months | Secondary: Secondary End point, Secondary end points will be improvement in vascular access flow rates as measured by either online conductivity dialysance or ultrasound dilution techniques., 12 months
|
| Sponsor/Collaborators: |
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Collaborators: Pfizer
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
17
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2011-12
|
| Completion Date: |
2022-03
|
| Results First Posted: |
|
| Last Update Posted: |
2022-05-16
|
| Locations: |
London Health Sciences Centre, London, Ontario, N6A 5A5, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT01595841
|
